<code id='80D1460F5F'></code><style id='80D1460F5F'></style>
    • <acronym id='80D1460F5F'></acronym>
      <center id='80D1460F5F'><center id='80D1460F5F'><tfoot id='80D1460F5F'></tfoot></center><abbr id='80D1460F5F'><dir id='80D1460F5F'><tfoot id='80D1460F5F'></tfoot><noframes id='80D1460F5F'>

    • <optgroup id='80D1460F5F'><strike id='80D1460F5F'><sup id='80D1460F5F'></sup></strike><code id='80D1460F5F'></code></optgroup>
        1. <b id='80D1460F5F'><label id='80D1460F5F'><select id='80D1460F5F'><dt id='80D1460F5F'><span id='80D1460F5F'></span></dt></select></label></b><u id='80D1460F5F'></u>
          <i id='80D1460F5F'><strike id='80D1460F5F'><tt id='80D1460F5F'><pre id='80D1460F5F'></pre></tt></strike></i>

          fashion

          fashion

          author:leisure time    Page View:6
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          FDA approves Moderna’s RSV vaccine, its second licensed product
          FDA approves Moderna’s RSV vaccine, its second licensed product

          TheFDAhasapprovedModerna’sRSVvaccineforolderadults.ModernaTheFoodandDrugAdministrationonFridayapprov

          read more
          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more

          Extensive review finds private equity owners jack up cost of care

          AdobePrivateequityfirmsarerapidlybuyingtheirwayintotheU.S.healthcaresystem,andastheydo,newresearchfi